RDY Short Long Term Debt vs Common Stock Analysis
| RDY Stock | USD 74.55 0.53 0.72% |
Dr Reddys financial indicator trend analysis is much more than just examining Dr Reddys Laboratories latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Dr Reddys Laboratories is a good investment. Please check the relationship between Dr Reddys Short Long Term Debt and its Common Stock accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Dr Reddys Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.
Short Long Term Debt vs Common Stock
Short Long Term Debt vs Common Stock Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Dr Reddys Laboratories Short Long Term Debt account and Common Stock. At this time, the significance of the direction appears to have very week relationship.
The correlation between Dr Reddys' Short Long Term Debt and Common Stock is 0.29. Overlapping area represents the amount of variation of Short Long Term Debt that can explain the historical movement of Common Stock in the same time period over historical financial statements of Dr Reddys Laboratories, assuming nothing else is changed. The correlation between historical values of Dr Reddys' Short Long Term Debt and Common Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Long Term Debt of Dr Reddys Laboratories are associated (or correlated) with its Common Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock has no effect on the direction of Short Long Term Debt i.e., Dr Reddys' Short Long Term Debt and Common Stock go up and down completely randomly.
Correlation Coefficient | 0.29 |
| Relationship Direction | Positive |
| Relationship Strength | Very Weak |
Short Long Term Debt
The total of a company’s short-term and long-term borrowings.Common Stock
Most indicators from Dr Reddys' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Dr Reddys Laboratories current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Dr Reddys Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. At this time, Dr Reddys' Tax Provision is fairly stable compared to the past year. Enterprise Value is likely to rise to about 740.6 B in 2024, whereas Selling General Administrative is likely to drop slightly above 39.7 B in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 113.8B | 203.0B | 233.4B | 245.1B | Total Revenue | 214.4B | 245.9B | 282.8B | 296.9B |
Dr Reddys fundamental ratios Correlations
Click cells to compare fundamentals
Dr Reddys Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Dr Reddys fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 232.2B | 265.5B | 296.7B | 322.9B | 371.3B | 206.1B | |
| Other Current Liab | 39.4B | 33.5B | 41.6B | 48.9B | 56.2B | 59.0B | |
| Total Current Liabilities | 72.8B | 81.5B | 97.8B | 85.7B | 98.6B | 68.3B | |
| Total Stockholder Equity | 155.0B | 175.0B | 190.5B | 232.9B | 267.8B | 281.2B | |
| Retained Earnings | 144.2B | 157.9B | 175.7B | 215.6B | 247.9B | 260.3B | |
| Accounts Payable | 10.7B | 21.9B | 25.6B | 22.7B | 26.1B | 15.0B | |
| Cash | 2.1B | 14.8B | 14.9B | 5.8B | 6.6B | 6.3B | |
| Other Assets | 14.8B | 11.6B | 13.7B | 7.1B | 8.2B | 8.6B | |
| Short Term Investments | 23.7B | 19.7B | 29.5B | 61.0B | 70.1B | 73.6B | |
| Inventory | 35.1B | 45.4B | 50.9B | 48.7B | 56.0B | 30.4B | |
| Total Liab | 77.3B | 90.5B | 106.1B | 90.0B | 103.5B | 88.4B | |
| Intangible Assets | 27.7B | 35.6B | 27.2B | 30.7B | 35.3B | 24.0B | |
| Property Plant Equipment | 52.3B | 57.1B | 62.2B | 66.3B | 76.2B | 80.1B | |
| Short Long Term Debt Total | 22.1B | 30.3B | 33.8B | 13.5B | 15.5B | 14.7B | |
| Other Liab | 3.5B | 3.1B | 2.7B | 2.5B | 2.9B | 3.1B | |
| Property Plant And Equipment Net | 52.3B | 57.1B | 62.2B | 56.5B | 65.0B | 54.0B | |
| Current Deferred Revenue | 1.9B | 2.0B | 2.6B | 2.0B | 1.8B | 1.7B | |
| Net Debt | 20.0B | 15.5B | 19.0B | 7.7B | 8.8B | 8.4B | |
| Non Current Assets Total | 101.9B | 117.2B | 115.5B | 118.6B | 136.4B | 95.9B | |
| Non Currrent Assets Other | 2.6B | 952M | 948M | 12.7B | 14.6B | 15.4B | |
| Cash And Short Term Investments | 25.7B | 34.6B | 44.4B | 66.7B | 76.8B | 80.6B | |
| Net Receivables | 61.8B | 52.4B | 70.0B | 72.5B | 83.4B | 46.9B | |
| Good Will | 4.0B | 4.6B | 4.4B | 5.5B | 6.3B | 6.6B | |
| Common Stock Shares Outstanding | 166.1M | 166.3M | 166.3M | 166.4M | 191.3M | 175.2M | |
| Liabilities And Stockholders Equity | 232.2B | 265.5B | 296.7B | 322.9B | 371.3B | 215.0B | |
| Non Current Liabilities Total | 4.4B | 9.0B | 8.3B | 4.3B | 4.9B | 4.7B | |
| Other Current Assets | 5.8B | 14.5B | 13.9B | 15.1B | 17.4B | 9.8B | |
| Other Stockholder Equity | 7.5B | 14.9B | 12.9B | 15.2B | 17.4B | 18.1B | |
| Total Current Assets | 130.4B | 148.2B | 181.1B | 204.3B | 234.9B | 120.7B | |
| Accumulated Other Comprehensive Income | 2.4B | 1.3B | 1.1B | 1.3B | 1.5B | 1.4B | |
| Short Term Debt | 20.8B | 24.0B | 28.1B | 12.2B | 14.0B | 27.5B | |
| Property Plant And Equipment Gross | 52.3B | 57.1B | 142.0B | 152.3B | 137.0B | 130.2B | |
| Net Tangible Assets | 91.9B | 123.3B | 134.8B | 158.9B | 182.7B | 102.9B | |
| Long Term Investments | 3.1B | 8.3B | 8.0B | 6.1B | 7.0B | 4.5B | |
| Short Long Term Debt | 20.3B | 24.0B | 28.1B | 12.2B | 11.0B | 17.2B | |
| Long Term Debt Total | 1.3B | 6.3B | 5.7B | 1.3B | 1.2B | 1.1B |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Dr Reddys in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Dr Reddys' short interest history, or implied volatility extrapolated from Dr Reddys options trading.
Currently Active Assets on Macroaxis
When determining whether Dr Reddys Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dr Reddys' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dr Reddys Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dr Reddys Laboratories Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Dr Reddys Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Dr Reddys Laboratories information on this page should be used as a complementary analysis to other Dr Reddys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Complementary Tools for RDY Stock analysis
When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |
Is Dr Reddys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dr Reddys. If investors know RDY will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dr Reddys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.103 | Dividend Share 40 | Earnings Share 3.76 | Revenue Per Share 272.4618 | Quarterly Revenue Growth 0.066 |
The market value of Dr Reddys Laboratories is measured differently than its book value, which is the value of RDY that is recorded on the company's balance sheet. Investors also form their own opinion of Dr Reddys' value that differs from its market value or its book value, called intrinsic value, which is Dr Reddys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dr Reddys' market value can be influenced by many factors that don't directly affect Dr Reddys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dr Reddys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dr Reddys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dr Reddys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.